ONCY: Seeking Registration Pathway for Part B of REO 033 Trial

ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics

Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY)

Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials

ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC

Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment

Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer

Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers